Expression of Survivin, CK7, ASH1, HMGB3, L587S, and CLCA2 in Peripheral Blood of Lung Cancer Patients by Real-Time Polymerase Chain Reaction

Introduction The objective of the present study was to identify gene expression in peripheral blood by a real-time polymerase chain reaction (PCR) technique in patients who have lung carcinoma. Material and methods Peripheral blood samples of patients with non-small cell and small cell lung cancer w...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2024-07, Vol.16 (7), p.e64386
Main Authors: Gupta, Sweety, Gupta, Manoj, Goyal, Bela, Yadav, Shashi Ranjan Mani, Mirza, Anissa A, Gupta, Amit, Rao, Shalinee, Kumari, Kusum, Nanda, Siddhartha, Kotru, Mrinalini
Format: Article
Language:English
Subjects:
Apoptosis
Biomarkers
Biopsy
Cancer therapies
Gene expression
Lung cancer
Medical prognosis
Metastasis
Oncology
Patients
Polymerase chain reaction
Pulmonology
Radiation Oncology
Sociodemographics
Squamous cell carcinoma
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction The objective of the present study was to identify gene expression in peripheral blood by a real-time polymerase chain reaction (PCR) technique in patients who have lung carcinoma. Material and methods Peripheral blood samples of patients with non-small cell and small cell lung cancer were collected. Target genes included survivin, CK7, ASH1, HMGB3, L587S, and CLCA2. β-Actin was the reference gene. If the mean C (threshold cycle) value for a target gene is ≥40, the gene expression is considered undetectable. Results Fifty patients with lung carcinoma were included and 30 healthy controls. Out of the six genes, survivin showed 26.8 times fold change as compared to controls; ASH1 and L587S were 0.54 and 0.06, respectively; and HMGB3, CLCA2, and CK7 had non-significant fold change in comparison to controls. The overall detection rate of the six target genes examined in lung cancer was 84%, with 42 out of 50 patients testing positive. Higher stages and ASH1 (p = 0.031), CK7 (p =
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.64386